This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
by Zacks Equity Research
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
by Zacks Equity Research
Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
by Zacks Equity Research
Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
by Zacks Equity Research
Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Sana (SANA) Have the Potential to Rally 78.23% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 78.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.